viewCynata Therapeutics Ltd

Cynata Therapeutics to talk stem cell therapies at Proactive’s CEO Sessions

Cynata’s managing director Dr Ross Macdonald will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

Cynata Therapeutics Ltd - Cynata Therapeutics to talk stem cell therapy at Proactive’s CEO Sessions
Cynata’s patented stem cell producing process, Cymerus™, has a number of key advantages

Cynata Therapeutics Ltd (ASX:CYP) is focused on using its proprietary Cymerus™ platform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders.

The trademark Cymerus refers to the patented process of generating cell-based products from intermediate cells

At present, Cynata is focused on the production of mesenchymal stem cell (MSC)-based products using the Cymerus technology.

An example of an MSC product is CYP-001, targeting graft-versus-host-disease (GvHD) for which a Phase I clinical trial has been completed.

During 2019, Fujifilm did a licensing deal with Cynata for CYP-001 and GvHD for a US$3 million upfront payment and future payments of up to US$43 million.

Aims to commercialise technology via further licence agreements

Cynata continues to focus on early commercialisation of Cynata’s Cymerus MSC products and is in active commercial discussions for numerous therapeutic targets.

During calendar year 2020, Cynata plans to be progressing to three Phase II trials in for GvHD (funded by Fujifilm), CLI, and osteoarthritis.

The company also continues to investigate the therapeutic potential in numerous additional target areas.

It is worth noting the Cymerus process has a number of key advantages including being only platform in the world able to produce commercial quantities of MSCs from a single source.

Five companies presenting

Five companies will present at the Sydney and Melbourne events, including Antisense Therapeutics Ltd (ASX:ANP), Recce Pharmaceuticals Ltd (ASX:RCE) and Great Boulder Resources Ltd (ASX:GBR).

The Sydney session will also include Reward Minerals Ltd (ASX:RWD) and the Melbourne session will include Alice Queen Ltd (ASX:AQX).

Register now for the CEO Sessions

Sydney event, Monday, February 3

Melbourne event, Tuesday, February 4

Quick facts: Cynata Therapeutics Ltd

Price: 0.82 AUD

Market: ASX
Market Cap: $96.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...


Cynata Therapeutics meets with New York investors following good news from...

Cynata Therapeutics Ltd (ASX:CYP) (OTCMKTS:CYYNF) CEO Ross Macdonald tells Proactive's Christine Corrado the cell therapy company has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute...

on 09/10/2018

2 min read